Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ada9.0
Adapalene – Forschung
Überwiegend Mechanismus / Beobachtung
32 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Adapalene sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1993–2026 mit einer typischen Studiengröße von 183 Teilnehmenden.
Basierend auf 32 Studien · 3 Meta-Analysen · 19 RCTs · 38,257 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Skin healthDeutliche Reduktion von komedonaler und entzündlicher Akne (Retinoid der ersten Wahl); am wirksamsten in Kombination mit Benzoylperoxid · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung17 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Muscle strength & power
Zu wenige bewertete Studien1 Studie
Men's vitality
Zu wenige bewertete Studien1 Studie
Therapeutic & clinical
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
25 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
199320092026
1Meta-Analysen=800 · large study2025
Future studies with larger, more diverse populations are recommended to confirm these findings and explore long-term efficacy.
This study aims to evaluate the efficacy and safety of clindamycin phosphate 1.2%/benzoyl peroxide 3% compared to clindamycin phosphate 1.2%/adapalene 0.1% combinations for treating acne vulgaris.
The meta-analysis of three RCTs demonstrated a significantly lower risk of TEAEs with CLIN/BPO (OR = 0.49, 95% CI: 0.35-0.86, p < 0.001).
CLIN/BPO also resulted in fewer application site side effects (OR = 0.33, 95% CI: 0.23-0.47, p < 0.001).
Further large-scale, comparative studies are needed to better define the optimal clinical use of advanced drug delivery systems for topical retinoids.
Tobiasz A, Jankowska-Konsur A, Nowicka D. · Pharmaceuticals (Basel, Switzerland) (2026)
Advances in formulation technologies have improved tolerability, while combination approaches with agents such as benzoyl peroxide, antibiotics or procedural techniques have shown additive or synergistic effects, particularly in more severe cases.
Nevertheless, much of the evidence regarding novel formulations is derived from small or heterogeneous study populations.
In conclusion, topical retinoids represent a relevant therapeutic option in acne vulgaris and acne scarring, from monotherapy in mild cases to components of multimodal treatment protocols in more severe disease.
5Systematische Übersichtn=33,472 · very large study2025
Combination agents are generally most effective for mild-to-moderate acne; however for non-inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
Kakpovbia EE, Young T, Milam EC, Qian Y, Yassin S, Nicholson J, Hu J, Troxel AB, Nagler AR. · Journal of the European Academy of Dermatology and Venereology : JEADV (2025)
Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale.
All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non-inflammatory lesion count reduction.
There was no significant difference amongst most single agents when evaluating lesion count reduction.
Approximately half of the participants achieved clear/almost clear skin, with >70% reductions in lesion counts.
Kircik LH, Harper JC, Baldwin H, Eichenfield LF, Tanghetti EA, Graber E, Woolery-Lloyd HC, Guenin E, Draelos ZD. · Journal of drugs in dermatology : JDD (2025)
Fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated superior efficacy to vehicle and component dyads with good safety/tolerability in 3 clinical trials of acne.
Results At week 12, approximately half of CAB-treated participants in both age groups achieved treatment success (9-24: 50.6%; greater than or equal to 25: 49.0%) vs less than one-fourth with vehicle (15.7%; 20.6%; P<0.01, both).
Across groups, CAB yielded >70% reductions in inflammatory/noninflammatory lesions vs 45% to 62% with vehicle (P≤0.001, all).
Ongoing education and research are essential to refine prescribing practices that balance therapeutic benefits with long-term patient and public health.
Issa NT, Baldwin H, Wroblewski K, Kircik L. · Journal of drugs in dermatology : JDD (2025)
Emerging evidence also links antibiotic use to reduced vaccine efficacy and diminished responses to cancer immunotherapy.
To mitigate these risks, dermatologists should prioritize narrow-spectrum antibiotics and incorporate combination topical therapies containing benzoyl peroxide (BPO), such as the triple-combination of clindamycin, adapalene, and BPO, to help curb antibiotic resistance.
Prudent antibiotic use, combined with topical regimens utilizing BPO, optimizes treatment outcomes while minimizing systemic adverse effects and resistance.
IDP-126 is therefore recommended to be applied as a thin layer to the affected area once daily.
Gupta AK, Mann A, Vincent K, Abramovits W. · Skinmed (2024)
Cabtreo TM (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) or IDP-126 topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged ≥12 years.
In Trial 1 (N = 183), treatment success was achieved in 49.6% (61/122) of subjects in the IDP-126 group versus 24.9% (15/61) of subjects in the vehicle group ( P < 0.01).
In Trial 2 (N = 180), treatment success was achieved in 50.5% (61/120) of subjects in the IDP-126 group versus 20.5% (12/60) of subjects in the vehicle group ( P < 0.01).
Harper JC, Kircik LH, Gold M, Hebert AA, Sugarman JL, Green L, Gold LS, Baldwin H, Guenin E, DelRosso JQ. · Journal of drugs in dermatology : JDD (2024)
This post hoc analysis compared threshold acne lesion reductions with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel—the first FDA-approved triple-combination topical acne product—to its dyads and vehicle.
The pooled percentage of participants achieving ≥33%, ≥50%, and ≥75% reduction in inflammatory and noninflammatory acne lesions was evaluated.
Results As early as week 4 in the phase 2 study, ≥33% reduction in inflammatory lesions occurred in a significantly greater percentage of CAB gel-treated participants (82.7%) than with the 3 dyads and vehicle (61.1-69.8%; P<0.05, all).
Eichenfield LF, Hebert AA, Harper JC, Baldwin H, Bhatia N, Gold LS, Kircik LH, Graber E, Tanghetti EA, Alexis AF, Del Rosso JQ. · Journal of drugs in dermatology : JDD (2024)
Background Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose triple-combination approved for acne (indicated in patients 12 years and older).
Endpoints included treatment success (at least 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin) and least-squares mean percent change from baseline in inflammatory/noninflammatory lesions.
Results At week 12, 51.5% of CAB-treated adolescents achieved treatment success vs 24.9% with vehicle (P<0.01).
Harper JC, Baldwin H, Choudhury SP, Rai D, Ghosh B, Aman MS, Choudhury AR, Dutta SK, Dey D, Bhattacharyya S, Lin T, Joseph G, Dashputre AA, Tan JKL. · Journal of drugs in dermatology : JDD (2024)
Efficacy outcomes included: percentage of patients achieving ≥2-grade reduction from baseline and “clear” or “almost clear” for global severity score (treatment success); absolute change in inflammatory (ILs reduction); and noninflammatory lesion counts (NILs reduction).
Topical triple-agent fixed-dose combination (FDC) gel (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) and combinations of double-agent fixed-dose topical treatments with oral antibiotics (TOA3) consistently ranked in the top 3 treatments.
Topical triple-agent FDC gel was numerically superior to TOA3 for treatment success (log-odds ratios: 1.84 [95% credible interval (CrI) 1.36 to 2.29]) and 1.69 (95% CrI: 1.01 to 2.32) vs placebo/vehicle).
Conclusion TAS in combination with AG was shown to improve mild-to-moderate acne with good tolerability and may effectively reduce the recurrence rate when applied as a maintenance treatment post-AG.
LYu J, Li J, Jiang Y, Wang S, Diao Q. · Journal of cosmetic dermatology (2026)
The control group showed rebound worsening after AG withdrawal.
Improvements in skin physiological parameters were observed in both groups, although without statistical significance.
Conclusions This open-label pilot study shows promising results for combination treatment with clascoterone cream 1% and adapalene gel 0.3% for the treatment of patients with acne.  .
Kircik L, Lamb AJ, Kircik A, Squittieri N, Kyeremateng K. · Journal of drugs in dermatology : JDD (2026)
Background Clascoterone cream 1% is a topical androgen receptor inhibitor approved for the treatment of acne vulgaris in patients ≥12 years of age.
This 20-week, open-label, pilot study (NCT06336603) evaluated the efficacy and safety of clascoterone cream 1% combined with adapalene gel 0.3% in patients with acne.
Methods Patients aged ≥12 years with moderate-to-severe acne applied clascoterone cream 1% twice daily and adapalene gel 0.3% once daily for 16 weeks.
Draelos ZD, Ghannoum M, Stein Gold L, Harper JC, Baldwin H, Guenin E, Tanghetti EA. · Journal of drugs in dermatology : JDD (2025)
In 12-week clinical trials, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) demonstrated efficacy and tolerability in the treatment of moderate to severe acne.
Results: At week 24, 68% of participants achieved treatment success (≥2-grade IGA score reduction from baseline and clear/almost clear skin), and significant inflammatory/noninflammatory lesion reductions from baseline were observed (89%; 70%; P<0.001, both).
Decreases from baseline in investigator- and participant-assessed PIH (77%; 82%) and PIE (84%; 88%) and investigator-assessed scarring severity (33%) were statistically significant (P≤0.001, all).
Baldwin H, Harper JC, Zeichner JA, Draelos ZD, Eichenfield LF, Gold M, Gold LS, Kircik LH. · Journal of drugs in dermatology : JDD (2024)
Introduction Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatment.
Results By week 12, all cases achieved >70% lesion reductions, 4/6 achieved treatment success, and 1/6 achieved a 2-grade reduction in severity.
All 6 CAB-treated cases achieved substantial (>70%) lesion reductions, with 5/6 achieving treatment success or 2-grade reduction in severity by week 12.
Draelos ZD. · Journal of drugs in dermatology : JDD (2024)
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB; Cabtreo®, Ortho Dermatologics) gel is the first triple-combination topical approved for the treatment of acne.
Results Investigator-assessed evenness of application favored CAB gel over layered application in 100% of participants.
Baldwin H, Gold LS, Harper JC, Alexis AF, Callender VD, Kircik L, Guenin E, Eichenfield LF. · Journal of drugs in dermatology : JDD (2024)
Background Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne.
Results At week 12, treatment success rates for both pediatric and adult participants were significantly greater with CAB (52.7%; 45.9%) than with vehicle (24.0%; 23.5%; P<0.01, both).
CAB-treated participants in both subgroups experienced greater reductions from baseline versus vehicle in inflammatory (pediatric: 78.6% vs 50.4%; adult: 76.6% vs 62.8%; P<0.001, both) and noninflammatory lesions (pediatric: 73.8% vs 41.1%; adult: 70.7% vs 52.2%; P<0.001, both).